Table 2 MLN2238 in combination with 10 µM A1210477 elicited synergistic inhibition of cell viability in HCC cells after 24 h of treatment

From: Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

 

HepG2

Hep3B

SNU475

 

A1210477

A1210477

A1210477

MLN2238 (nM)

31.25

0.703

0.543

1.030

62.5

0.572

0.605

0.659

125

0.754

0.524

0.368

250

0.784

0.490

0.268

500

1.129

0.414

0.258

1000

1.453

0.456

0.209

  1. The combination index (CI) values are indicated. CalcuSyn software was used to calculate the CI, where a CI < 1 indicated synergy,~1 indicated an additive effect and >1 indicated antagonism
Back to article page